Home/Pipeline/Neoantigen Based Cancer Therapy

Neoantigen Based Cancer Therapy

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Hexamer Therapeutics

About Hexamer Therapeutics

Hexamer Therapeutics is a private, pre-clinical stage biotech developing a next-generation, self-assembling peptide vaccine platform. The technology is designed for rapid engineering and scalability, targeting both mutating infectious diseases (SARS-CoV-2) and personalized cancer vaccines. The company is led by a seasoned team with deep experience in genomics, vaccine development, and cancer research, and has secured non-dilutive funding from the US Army for its infectious disease program.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active